Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5310074 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | multiple doses |
| RO5310074 | DRUG | multiple ascending doses |
Inclusion Criteria: * Adult patients, 18 - 75 years of age * Diagnosis of Psoriatic Arthritis (Moll and Wright or CASPAR criteria) of \>/= 6 months duration * Have \>/= 3 swollen and \>/= 3 tender joints * Inadequate response to a current or previous oral DMARD or NSAID therapy * Current oral DMARD...
RO5310074 is an investigational small molecule being developed for the treatment of psoriatic arthritis. It is being studied in patients with this condition, and the clinical trial for this indication has been completed.
RO5310074 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is investigating this small molecule for the treatment of psoriatic arthritis.
RO5310074 is in Phase 1 clinical development. A Phase 1 study in patients with psoriatic arthritis has been completed, and the drug remains investigational, meaning it is not yet approved for any use.
RO5310074 has one completed clinical trial, identified as NCT01199809, titled "A Study of RO5310074 in Patients With Psoriatic Arthritis." This Phase 1 study enrolled 19 participants and was conducted in the United States, Australia, and New Zealand.
RO5310074 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial for psoriatic arthritis, but it has not received approval from the FDA or any other regulatory authority.